WeightCare Review
Best for: patients prioritizing pharmacy quality standards (PCAB) with coaching support
WeightCare offers compounded semaglutide ($249–$399/mo) and tirzepatide ($349/mo) dispensed by FDA-registered, PCAB-accredited pharmacies. Based in Ft. Lauderdale, FL. Claims 85,000+ members since 2022. Quality testing documentation (potency + sterility per USP 797).
Medium confidence · Last verified 2026-04-10 via WebFetch · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
WeightCare is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
WeightCare prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Semaglutide Lite/Essentials | compounded | $249 |
| Semaglutide Select | compounded | $299 |
| Semaglutide Weight Loss | compounded | $399 |
| Semaglutide Micro-Dose | compounded | $249 |
| Tirzepatide Essentials | compounded | $349 |
✓ Pros
- •PCAB-accredited pharmacy partners — strongest pharmacy quality signal
- •Quality testing: potency and sterility per USP 797 standards
- •85,000+ members since 2022 — established patient base
- •Multiple program tiers for semaglutide
- •Health coaching, dietitians, fitness trainers included
- •Physical address in Ft. Lauderdale FL
✗ Cons
- •No LegitScript certification on the site itself
- •State availability not explicitly listed
- •Pricing above average ($249–$399/mo for semaglutide)
- •Compounded only — no brand-name options
Ready to start with WeightCare?
Starting at $249/month. See current pricing and start your free consultation.
Sources & methodology
Our WeightCare review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to WeightCare
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with WeightCare?
Starting at $249/month. See current pricing and start your free consultation.